lumakrashcp.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | KRAS G12C–Mutated NSCLC Oral Therapy | LUMAKRAS® |
| Description | It’s time to move forward with Learn about LUMAKRAS®(sotorasib), a KRAS G12C inhibitor used to treat locally advanced or metastatic NSCLC following first line of |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 54.148.237.9 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
lumakrashcp.com Valuation
|
US$13,283,313
Last updated: 2023-05-01 08:29:12
lumakrashcp.com has Semrush global rank of 796,812. lumakrashcp.com has an estimated worth of US$ 13,283,313, based on its estimated Ads revenue. lumakrashcp.com receives approximately 1,532,690 unique visitors each day. Its web server is located in United States, with IP address 54.148.237.9. According to SiteAdvisor, lumakrashcp.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$13,283,313 |
| Daily Ads Revenue | US$12,262 |
| Monthly Ads Revenue | US$367,846 |
| Yearly Ads Revenue | US$4,414,148 |
| Daily Unique Visitors | 102,180 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| lumakrashcp.com. | A | 300 | IP: 54.148.237.9 |
| lumakrashcp.com. | A | 300 | IP: 54.201.250.38 |
| lumakrashcp.com. | NS | 86400 | NS Record: ns-1362.awsdns-42.org. |
| lumakrashcp.com. | NS | 86400 | NS Record: ns-2000.awsdns-58.co.uk. |
| lumakrashcp.com. | NS | 86400 | NS Record: ns-313.awsdns-39.com. |
| lumakrashcp.com. | NS | 86400 | NS Record: ns-878.awsdns-45.net. |
HtmlToTextCheckTime:2023-05-01 08:29:12
| INDICATION LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Prescribing Information Indication Important Safety Information Patient Site Connect with Amgen LUMAKRAS • loo-ma-krass SOTORASIB • soh-toh-rass-ib --> About KRAS G12C Prevalence KRAS G12C inhibition Efficacy CodeBreaK 100 ORR Depth of response OS PFS Study design Baseline characteristics EAP Key safety Treatment duration PFS Study design Baseline characteristics Safety Dosing Dosing Dose modifications Coadministration Testing Why to test How to test Reporting Support Amgen |
HTTP Headers
HTTP/1.1 403 Forbidden Server: awselb/2.0 Date: Sat, 23 Oct 2021 23:08:59 GMT Content-Type: text/html Content-Length: 118 Connection: keep-alive |
lumakrashcp.com Whois Information
Domain Name: LUMAKRASHCP.COM Registry Domain ID: 2552285609_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2020-12-18T16:15:52Z Creation Date: 2020-08-11T16:18:24Z Registry Expiry Date: 2022-08-11T16:18:24Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-1362.AWSDNS-42.ORG Name Server: NS-2000.AWSDNS-58.CO.UK Name Server: NS-313.AWSDNS-39.COM Name Server: NS-878.AWSDNS-45.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-12T08:24:02Z <<< |